SG149684A1 - A virus causing respiratory tract illness in susceptible animals - Google Patents

A virus causing respiratory tract illness in susceptible animals

Info

Publication number
SG149684A1
SG149684A1 SG200504408-6A SG2005044086A SG149684A1 SG 149684 A1 SG149684 A1 SG 149684A1 SG 2005044086 A SG2005044086 A SG 2005044086A SG 149684 A1 SG149684 A1 SG 149684A1
Authority
SG
Singapore
Prior art keywords
respiratory tract
virus causing
causing respiratory
tract illness
susceptible animals
Prior art date
Application number
SG200504408-6A
Other languages
English (en)
Inventor
Jong Jan De
Ronaldus Adrianus Maria Fouchier
Den Hoogen Bernadetta Gerarda Van
Albertus Dominicus Marcellinus Erasm Osterhaus
Jan Groen
Original Assignee
Vironovative Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26076820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG149684(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vironovative Bv filed Critical Vironovative Bv
Publication of SG149684A1 publication Critical patent/SG149684A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18341—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
SG200504408-6A 2001-01-19 2002-01-18 A virus causing respiratory tract illness in susceptible animals SG149684A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01200213 2001-01-19
EP01203985 2001-10-18

Publications (1)

Publication Number Publication Date
SG149684A1 true SG149684A1 (en) 2009-02-27

Family

ID=26076820

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200504408-6A SG149684A1 (en) 2001-01-19 2002-01-18 A virus causing respiratory tract illness in susceptible animals

Country Status (21)

Country Link
US (10) US8927206B2 (enExample)
EP (1) EP1351981B1 (enExample)
JP (3) JP5503096B2 (enExample)
KR (4) KR101105984B1 (enExample)
CN (2) CN1524088B (enExample)
AU (1) AU2002228471B2 (enExample)
BR (1) BR0206591A (enExample)
CA (1) CA2435180C (enExample)
DK (1) DK1351981T3 (enExample)
EA (1) EA006879B1 (enExample)
ES (1) ES2393468T3 (enExample)
HU (1) HUP0500244A3 (enExample)
IL (1) IL157003A0 (enExample)
MX (1) MXPA03006430A (enExample)
NO (1) NO335551B1 (enExample)
NZ (2) NZ527221A (enExample)
PL (1) PL213926B1 (enExample)
SG (1) SG149684A1 (enExample)
UA (1) UA93981C2 (enExample)
WO (1) WO2002057302A2 (enExample)
ZA (1) ZA200305655B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094105A1 (en) 1998-04-24 2006-05-04 University Hospitals Of Cleveland Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses
US20030232061A1 (en) * 2001-10-18 2003-12-18 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
WO2002057302A2 (en) 2001-01-19 2002-07-25 Vironovative B.V. A virus causing respiratory tract illness in susceptible mammals
EP2327418A1 (en) 2002-02-21 2011-06-01 MedImmune, LLC Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from other viruses
DE10221836A1 (de) * 2002-05-16 2003-12-04 Lohmann Animal Health Gmbh Attenuierung von Metapneumovirus
TW200501985A (en) * 2002-07-25 2005-01-16 Medimmune Inc Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
AU2003297602A1 (en) * 2002-12-02 2004-06-23 University Of Maryland, College Park Avian pneumovirus genes, recombinant avian pneumoviruses and methods of making
WO2004057021A2 (en) * 2002-12-19 2004-07-08 UNIVERSITé LAVAL Molecular methods and compositions for detecting and quantifying respiratory viruses
EP1603939A2 (en) * 2003-02-28 2005-12-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Recombinant human metapneumovirus and its use
WO2004085650A1 (en) 2003-03-24 2004-10-07 The University Of Hong Kong A high-troughput diagnostic assay for the human virus causing severe acute respiratory syndrome (sars)
ATE469170T1 (de) * 2003-03-28 2010-06-15 Medimmune Llc Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
JP4764818B2 (ja) * 2003-04-11 2011-09-07 メディミューン，エルエルシー 組換えｉｌ−９抗体およびその使用
JP2006524511A (ja) * 2003-04-25 2006-11-02 メッドイミューン バクシーンズ，インコーポレイティド メタニューモウイルス由来の異種抗原を含む組換えパラインフルエンザウイルス発現系およびワクチン
EP2494987A1 (en) 2003-04-25 2012-09-05 MedImmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
EP1473037A1 (en) * 2003-05-02 2004-11-03 Vironovative B.V. Treatment of hPMV infections with Ribavirin
JP2007505618A (ja) * 2003-09-22 2007-03-15 インスティティ・パスツール ニパウイルスの検出方法及びヘニパウイルスに対する免疫保護を提供する方法
JP4879884B2 (ja) 2004-04-12 2012-02-22 メディミューン，エルエルシー 抗−ｉｌ−９抗体製剤及びその使用法
JP4546212B2 (ja) * 2004-10-21 2010-09-15 三菱化学メディエンス株式会社 抗原蛋白質を発現した細胞を利用する抗体測定方法
KR20070110924A (ko) * 2005-03-10 2007-11-20 메드이뮨 백신즈 인코포레이티드 메타뉴모바이러스주 및 항원성 서열의 발현용 벡터 및 백신제제로서의 이의 용도 및 바이러스의 증식 방법
US20080175836A1 (en) * 2005-12-09 2008-07-24 Karp Nelson M Immunogenic composition based on conditionally live virion and method for producing the same
US8492097B2 (en) 2006-04-24 2013-07-23 Diagnostic Hybrids, Inc. Compositions and methods for human metapneumovirus monoclonal antibodies
EP2069485A4 (en) * 2007-07-13 2011-05-25 Medimmune Llc PREPARATION OF NEGATIVE STRAND RNA VIRUSES BY ELECTROPORATION
WO2009062532A1 (en) * 2007-11-16 2009-05-22 Vironovative Bv Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
US20090186050A1 (en) * 2007-11-16 2009-07-23 Fouchier Ron A M Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
US20120251502A1 (en) 2008-10-24 2012-10-04 The Government of the US as Represented by the Secretary of the Dept. of health Human Ebola Virus Species and Compositions and Methods Thereof
KR101073991B1 (ko) * 2009-10-27 2011-10-21 대한민국 국내사육 닭에서 유행하는 신규한 ｂ형 조류메타뉴모바이러스 ｓｃ1509주 및 이의 용도
CN101880732B (zh) * 2010-06-29 2012-10-10 中国药品生物制品检定所 猴副流感病毒5型的rt-pcr检测方法及试剂盒
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN103429606A (zh) 2010-10-01 2013-12-04 现代治疗公司 设计核酸及其使用方法
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
NZ630920A (en) 2012-03-20 2017-01-27 Humabs Biomed Sa Antibodies that neutralize rsv, mpv and pvm and uses thereof
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EA039682B1 (ru) * 2012-06-04 2022-02-28 Хумабс Биомед Са Антитела, нейтрализующие rsv, mpv и pvm, и их применения
CN102676701B (zh) * 2012-06-11 2013-08-14 广东温氏食品集团股份有限公司 禽肺病毒通用型rt-pcr检测引物及检测方法
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
WO2014115893A1 (ja) 2013-01-28 2014-07-31 株式会社イーベック ヒト・メタニューモウイルスに特異的なヒト抗体もしくはその抗原結合性断片
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CN103360472B (zh) * 2013-07-30 2015-02-25 北京市农林科学院 禽偏肺病毒抗体elisa检测试剂盒
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CL2013002829A1 (es) * 2013-10-01 2014-04-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
US10774114B2 (en) * 2014-03-10 2020-09-15 Fondation The Ark Respiratory syncytial virus (RSV) replication inhibitors
EP3718565B1 (en) 2015-10-22 2022-04-27 ModernaTX, Inc. Respiratory virus vaccines
DE102016215118A1 (de) 2016-08-12 2018-02-15 Anicon Labor Gmbh Infektiöse Bronchitis (IB)-Virus Varianten und diesbezügliche Zusammensetzungen, Verwendungen und Verfahren
US10232033B2 (en) * 2016-10-31 2019-03-19 Wuhan Sanli BioTechnology Company Limited Respiratory syncytial virus vaccine
US11103578B2 (en) 2016-12-08 2021-08-31 Modernatx, Inc. Respiratory virus nucleic acid vaccines
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
KR20210005090A (ko) * 2018-04-23 2021-01-13 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 키메라 벡터
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US20240279610A1 (en) 2021-06-09 2024-08-22 Universität Duisburg-Essen Method for immortalising vesicle-secreting cells
WO2023004307A1 (en) * 2021-07-19 2023-01-26 Epivax, Inc. T cell epitopes and related compositions useful in the prevention and treatment of respiratory syncytial virus infection

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0413695B1 (en) 1988-04-22 1994-05-04 The Upjohn Company Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3.
US5137819A (en) 1988-07-08 1992-08-11 University Of British Columbia Cellulose binding fusion proteins for immobilization and purification of polypeptides
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5854037A (en) * 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
GB9200117D0 (en) 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
CA2188317A1 (en) 1994-04-19 1995-10-26 Ronaldus Adrianus Maria Fouchier Nucleic acids and methods for the discrimination between syncytium inducing and non syncytium inducing variants of the human immunodeficiency virus
SE504386C2 (sv) 1994-05-30 1997-01-27 Bengt Wilhelm Toernqvist Bottenkonstruktion på ett deplacementfartygsskrov
ATE257175T1 (de) 1994-07-18 2004-01-15 Conzelmann Karl Klaus Prof Dr Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
ATE181112T1 (de) 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
CA2230033C (en) 1995-09-27 2010-01-26 Peter L. Collins Production of infectious respiratory syncytial virus from cloned nucleotide sequences
US5869036A (en) * 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine
ES2109189B1 (es) 1996-03-14 1998-05-16 Iberica Cyanamid Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas.
US6180398B1 (en) * 1996-07-12 2001-01-30 Virogeneitics Corporation Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation
CN101012454B (zh) 1996-07-15 2011-11-16 美国政府健康及人类服务部 从克隆的核苷酸序列制备减毒呼吸道合胞病毒疫苗的方法
CN1232504A (zh) 1996-09-27 1999-10-20 美国氰胺公司 在单链负义病毒目病毒内引起减毒的3'基因组启动子区和聚合酶基因中的突变
US5817494A (en) 1997-05-21 1998-10-06 Incyte Pharmaceuticals, Inc. Ubiquitin conjugation proteins
AU7797798A (en) 1997-05-23 1998-12-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
US7192593B2 (en) * 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
PT1012244E (pt) 1997-07-11 2007-08-21 Univ Yale ''rabdovírus com revestimentos remanipulados''
EP1015594A1 (en) 1997-09-19 2000-07-05 American Cyanamid Company Attenuated respiratory syncytial viruses
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
AU6200399A (en) * 1998-10-05 2000-04-26 Akzo Nobel N.V. Avian pneumovirus vaccine and diagnostic agent
WO2000070070A1 (en) 1999-05-18 2000-11-23 Dnavec Research Inc. Paramyxoviridae virus vector defective in envelope gene
CN101392239A (zh) 1999-07-09 2009-03-25 美国政府健康及人类服务部 减毒的人-牛嵌合副流感病毒(piv)疫苗
KR100454451B1 (ko) 1999-07-29 2004-10-28 하테부르 움포름마쉬넨 아크티엔게젤샤프트 상승 및 하강 이동 발생장치
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
CA2362685A1 (en) 1999-12-10 2001-06-14 Brian R. Murphy Use of recombinant parainfluenza viruses (pivs) as vectors to protect against infection and disease caused by piv and other human pathogens
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
US6387586B1 (en) 2000-11-06 2002-05-14 Eastman Kodak Company High contrast visually adaptive radiographic film and imaging assembly for thoracic imaging
AU3652202A (en) 2000-11-28 2002-06-11 Aviron Inc Recombinant rsv virus expression systems and vaccines
US6632459B2 (en) 2000-12-11 2003-10-14 Nutricia N.V. Chlorogenic acid and an analog thereof for immune system stimulation
WO2002057302A2 (en) * 2001-01-19 2002-07-25 Vironovative B.V. A virus causing respiratory tract illness in susceptible mammals
US8715922B2 (en) * 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
US20030232061A1 (en) * 2001-10-18 2003-12-18 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
ATE509097T1 (de) 2001-11-21 2011-05-15 Us Health Gewinnung von rekombinantem menschlichem parainfluenzavirus typ 1 (hpivi) aus cdna
EP2327418A1 (en) * 2002-02-21 2011-06-01 MedImmune, LLC Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from other viruses
DE10221836A1 (de) 2002-05-16 2003-12-04 Lohmann Animal Health Gmbh Attenuierung von Metapneumovirus
TW200501985A (en) 2002-07-25 2005-01-16 Medimmune Inc Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
US6605283B1 (en) * 2002-11-01 2003-08-12 The United States Of America As Represented By The Secretary Of Agriculture Nucleotide sequence for the Avian Metapneumovirus (Colorado) attachment glycoprotein gene
WO2004057021A2 (en) 2002-12-19 2004-07-08 UNIVERSITé LAVAL Molecular methods and compositions for detecting and quantifying respiratory viruses
EP1603939A2 (en) 2003-02-28 2005-12-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Recombinant human metapneumovirus and its use
KR20050109527A (ko) 2003-03-05 2005-11-21 코닌클리케 필립스 일렉트로닉스 엔.브이. 광학매체의 정보를 기록/소거하기 위한 전력 파라미터결정장치 및 방법
JP2007528700A (ja) 2003-04-08 2007-10-18 コロノヴァティブ ビー．ブイ． Ｓａｒｓ
EP2494987A1 (en) 2003-04-25 2012-09-05 MedImmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
JP2006524511A (ja) * 2003-04-25 2006-11-02 メッドイミューン バクシーンズ，インコーポレイティド メタニューモウイルス由来の異種抗原を含む組換えパラインフルエンザウイルス発現系およびワクチン
WO2005007078A2 (en) * 2003-04-30 2005-01-27 The Boards Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (sars)
EP1533370A1 (en) 2003-11-18 2005-05-25 ViroNovative B.V. Novel atypical pneumonia-causing virus
EP1548748A1 (en) 2003-12-17 2005-06-29 Interuniversitaire Microelectronica Centrum vzw ( IMEC) A method for making probes for atomic force microscopy
WO2005080991A1 (en) 2004-02-20 2005-09-01 Erasmus Universiteit Rotterdam Method to detect antigen-specific cytolytic activity
US8318423B2 (en) 2004-07-06 2012-11-27 Focus Diagnostics, Inc. Methods and compositions for detecting rhinoviruses
US20080292658A1 (en) 2004-11-11 2008-11-27 Emmie De Wit Defective Influenza Virus Particles
BRPI0518568A2 (pt) 2004-12-24 2008-11-25 Solvay Pharm Bv mÉtodo para produzir uma partÍcula do vÍrus da influenza replicativo sem o uso de vÍrus auxiliar, partÍcula de vÍrus da influenza replicativo, cÉlula, composiÇço, uso de uma composiÇço, mÉtodo para gerar proteÇço imunolàgica contra infecÇço de um indivÍduo com um vÍrus da influenza, e, Ácido nuclÉico
KR20070110924A (ko) * 2005-03-10 2007-11-20 메드이뮨 백신즈 인코포레이티드 메타뉴모바이러스주 및 항원성 서열의 발현용 벡터 및 백신제제로서의 이의 용도 및 바이러스의 증식 방법
WO2006110214A2 (en) * 2005-04-08 2006-10-19 Medimmune, Inc. Antibodies against mammalian metapneumovirus
EP1748447B1 (en) 2005-07-28 2008-10-22 Interuniversitair Microelektronica Centrum ( Imec) Dual tip atomic force microscopy probe and method for producing such a probe
EP1925318A1 (en) 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US20090186050A1 (en) 2007-11-16 2009-07-23 Fouchier Ron A M Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
CN107281478B (zh) 2010-07-23 2022-04-01 诺瓦瓦克斯公司 流感疫苗
JP5923723B2 (ja) 2011-06-02 2016-05-25 パナソニックＩｐマネジメント株式会社 人物属性推定システム、人物属性推定装置、及び人物属性推定方法
WO2014045254A2 (en) 2012-09-23 2014-03-27 Erasmus University Medical Center Rotterdam Human betacoronavirus lineage c and identification of n-terminal dipeptidyl peptidase as its virus receptor
CN109402065B (zh) * 2018-08-08 2021-07-30 温氏食品集团股份有限公司 一种番鸭c亚型禽偏肺病毒弱毒株及其制备和应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"COST-EFFECTIVENESS OF RESPIRATORY SYNCITIAL VIRUS PROPHYLAXIS AMONG PRETERM INFANTS" *
"EBI DATBASE ACCESSION Q9QF47", EBI DATABASE ACCESSION Q9QF44", EBI *
"HUMAN METAPNUEMOVIRUS ISOLATE 00-1, COMPLETE GENOME" *

Also Published As

Publication number Publication date
CN1524088A (zh) 2004-08-25
WO2002057302A2 (en) 2002-07-25
KR100964413B1 (ko) 2010-06-15
ZA200305655B (en) 2004-07-22
US20170183747A1 (en) 2017-06-29
JP5503096B2 (ja) 2014-05-28
EP1351981B1 (en) 2012-08-08
CN101921732A (zh) 2010-12-22
CA2435180C (en) 2019-04-09
UA93981C2 (ru) 2011-03-25
EA006879B1 (ru) 2006-04-28
ES2393468T3 (es) 2012-12-21
DK1351981T3 (da) 2012-11-26
US20140295409A1 (en) 2014-10-02
WO2002057302A8 (en) 2003-11-13
EP1351981A2 (en) 2003-10-15
KR101412317B1 (ko) 2014-07-24
US20200140964A1 (en) 2020-05-07
JP5813060B2 (ja) 2015-11-17
KR101105984B1 (ko) 2012-01-18
EA200300810A1 (ru) 2003-12-25
BR0206591A (pt) 2005-02-01
NO335551B1 (no) 2014-12-29
US9376726B2 (en) 2016-06-28
JP2011177173A (ja) 2011-09-15
CN1524088B (zh) 2012-11-07
US11162148B2 (en) 2021-11-02
WO2002057302A3 (en) 2002-12-27
US9334543B2 (en) 2016-05-10
KR20040002853A (ko) 2004-01-07
JP2004531220A (ja) 2004-10-14
AU2002228471B2 (en) 2008-02-14
US20040005544A1 (en) 2004-01-08
HUP0500244A3 (en) 2011-03-28
US9593386B2 (en) 2017-03-14
HUP0500244A2 (hu) 2005-05-30
NO20033272D0 (no) 2003-07-18
HK1068898A1 (en) 2005-05-06
US20190119762A1 (en) 2019-04-25
US10167524B2 (en) 2019-01-01
PL213926B1 (pl) 2013-05-31
NO20033272L (no) 2003-09-18
PL367826A1 (en) 2005-03-07
KR20110113658A (ko) 2011-10-17
US20150093746A1 (en) 2015-04-02
NZ527221A (en) 2006-09-29
KR20100034059A (ko) 2010-03-31
US20180057893A1 (en) 2018-03-01
US7531342B2 (en) 2009-05-12
JP2014027930A (ja) 2014-02-13
MXPA03006430A (es) 2004-10-15
IL157003A0 (en) 2004-02-08
US10519517B2 (en) 2019-12-31
US8927206B2 (en) 2015-01-06
US20160244850A1 (en) 2016-08-25
US20100143407A1 (en) 2010-06-10
KR20090006236A (ko) 2009-01-14
NZ555567A (en) 2008-07-31
US9803252B2 (en) 2017-10-31
CA2435180A1 (en) 2002-07-25
US20050118195A1 (en) 2005-06-02
US8722341B2 (en) 2014-05-13

Similar Documents

Publication Publication Date Title
SG149684A1 (en) A virus causing respiratory tract illness in susceptible animals
WO2004001019A3 (en) Novel nanoparticles and use thereof
WO2005074990A3 (en) Methods of preventing and treating sars using low ph respiratory tract compositions
AR027387A1 (es) Metodo de filtrcion de una corriente lactea.
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
DK1458360T3 (da) Pulmonær afgivelse af aminoglycosider
WO2004089983A3 (en) Severe acute respiratory syndrome (sars) causing coronavirus
NO20042143L (no) Fremgangsmate for fremstilling av raskt opplosende preparater med hoyt innhold av ribavirin
BR0302369A (pt) Conjunto de elementos para estruturas de montagem
WO2006062596A3 (en) RNAi MODULATION OF RSV, PIV AND OTHER RESPIRATORY VIRUSES AND USES THEREOF
WO2006096459A3 (en) Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
WO2006038908A3 (en) Ancestral and cot viral sequences, proteins and immunogenic compositions
EP1371373A4 (en) RECOMBINANT SUPERCOMPOSE INTERFERON AS INHIBITOR OF SURFACE ANTIGEN AND ANTIGEN E OF HEPATITIS B
DE60231611D1 (de) Verabreichung von opioiden durch inhalation
MX2025004821A (es) Moleculas de arn que codifican el vrs-f y vacunas que las contienen
WO2004099240A3 (en) Peptides and mixtures thereof for use in the detection of severe acute respiratory syndrome-associated coronavirus (sars)
WO2005049814A3 (en) Novel atypical pneumonia-causing virus
DE50304242D1 (de) Verfahren zur herstellung von acylphosphinoxiden
WO2007064844A3 (en) Anti-viral griffithsin compounds, compositions, and methods of use
WO2005002511A3 (en) Recombinant antibodies and compositions and methods for making and using the same
WO2007002639A3 (en) Non-nucleoside anti-hepacivirus agents and uses thereof
ECSP024237A (es) Composicion y método para inducir tolerancia en contra de infecciones virales en animales acuaticos
AU2002317474A1 (en) Human recombinant antibody against the hepatitis c (hcv) non structural ns3 protein, nucleic acid and uses thereof
WO2004082596A3 (en) Yersinia species compositions
WO2004037202A3 (en) Gb virus c and methods of treating viral infections